Gilead in tested channel
GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.
Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel, meaning the Risk-Reward-Ratio is at a good stance.
A close below the 50sma would change the sentiment, and remove us from the channel.
Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel, meaning the Risk-Reward-Ratio is at a good stance.
A close below the 50sma would change the sentiment, and remove us from the channel.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.